KRAS and colorectal carcinoma: Current therapeutic approaches targeting RAS-related tumors show limited efficacy, particularly in patients with KRAS-mutant metastatic CRC (Nazarian et al., 2010; Misale et al., 2012; Stephen et al., 2014).